Research indicates a link between COVID-19 severity, Chronic Fatigue Syndrome, and plasma NF-L concentrations, suggesting that NF-L could serve as an effective biomarker for neurodegenerative diseases and axonal damage [26]. This evidence concerns the gene NEFL and COVID-19.